Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients
- 52 Downloads
Diffuse gliomas are the most common malignant primary brain tumors and remain incurable. A better knowledge of the tumor etiology is required. Specific single nucleotides polymorphisms (SNPs) rs4977756 (CDKN2A/B), rs6010620 (RTEL1), rs498872 (PHLDB1), rs2736100 (TERT), and rs4295627 (CCDC26) have been associated with glioma susceptibility and are potential risk biomarkers. This study aimed to analyze five SNPs associated with glioma susceptibility, in the Portuguese population. SNPs were genotyped using the Sequenom MassARRAY platform in 127 gliomas and 180 controls. Unconditional logistic regression models were used to calculate odds ratio (OR) and 95% confidence intervals. The false-positive report probability was also assessed. The associations between polymorphisms and survival were evaluated using the log-rank test. It was found that the AG and GG genotypes of the rs4977756 (CDKN2A/B) were associated with an increased risk of gliomas (OR 1.85 and OR 2.38) and glioblastomas (OR 2.77 and OR 3.94). The GA genotype of the rs6010620 (RTEL1) was associated with a decreased risk of glioblastomas (OR 0.45). We also observed that the GA genotype of the rs498872 (PHLDB1) was associated with an increased risk of gliomas (OR 2.92) and glioblastomas (OR 2.39). No significant risk associations were found for the rs2736100 (TERT) and rs4295627 (CCDC26). In addition, the genotype AA of the rs498872 (PHLDB1) was associated with poor overall survival of gliomas patients (AA vs. GA, p = 0.037). The rs6010620 (RTEL1), rs4977756 (CDKN2A/B), and rs498872 (PHLDB1) are associated with glioma risk in the Portuguese population and these data may contribute to understanding gliomas etiology.
KeywordsGlioma risk SNPs GWAS RTEL1 CDKN2A/B PHLDB1
Coiled-coil domain containing 26
Cyclin-dependent kinase inhibitor 2A/B
False-positive report probability
Genome-wide association studies
Pleckstrin Homology-Like Domain Family B member 1
Regulator of telomere elongation helicase 1
Single nucleotide polymorphisms
Telomerase reverse transcriptase
World Health Organization
MV-P: Genotyping of samples, analysis of polymorphisms and patient’s data, tables and figures, manuscript review; DAM: interpreted genotyping, patient’s data, bibliography review, manuscript writing; PL, JA, RN and RV: clinical data collection, interpretation and final review; SC: collections of samples, DNA extraction, genotyping; RMR: study design, scientific support, results analysis, manuscript review, research coordination.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Fundacão para a Ciência e Tecnologia (FCT), Portugal (www.fct.pt; grant PTDC/SAU-ONC/115513/2009_FCOMP-01-0124-FEDER-015949 to R.M.R.). This article has been developed under the scope of the project NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). M.V.P. was recipient of an FCT Post-Doctoral fellowship (ref: SFRH/BPD/104290/2014).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Institutional ethics committees of S. João and Braga Hospitals (Approval 29/10/2007).
Not applicable. This is a retrospective study where any information that allows participants identification is not disclosed.
- 6.Batista R, Cruvinel-Carloni A, Vinagre J, Peixoto J, Catarino TA, Campanella NC et al (2016) The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. Int J Cancer 139(2):414–423. https://doi.org/10.1002/ijc.30057 CrossRefPubMedGoogle Scholar
- 16.McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P et al (2009) Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev 18(4):1118–1126. https://doi.org/10.1158/1055-9965.EPI-08-1078 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H (2009) Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol 19(2):188–194. https://doi.org/10.1111/j.1750-3639.2008.00170.x CrossRefPubMedGoogle Scholar
- 27.Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U et al (2016) Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. J Neurooncol 127(3):483–492. https://doi.org/10.1007/s11060-016-2066-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Coetzee SG, Rhie SK, Berman BP, Coetzee GA, Noushmehr H (2012) FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. Nucleic Acids Res 40(18):e139. https://doi.org/10.1093/nar/gks542 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Hirano T (2016) The role of the CCDC26 long noncoding RNA as a tumor suppressor. RNA Dis 3:e1022Google Scholar
- 42.Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y et al (2011) Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 204(1):13–18. https://doi.org/10.1016/j.cancergencyto.2010.10.002 CrossRefPubMedPubMedCentralGoogle Scholar